Multicenter Phase II Study of FOLFOX/XELOX and Erbitux as First Line Therapy in Patients with Wild Type KRAS/BRAF Metastatic Colorectal Cancer.

Trial Profile

Multicenter Phase II Study of FOLFOX/XELOX and Erbitux as First Line Therapy in Patients with Wild Type KRAS/BRAF Metastatic Colorectal Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2018

At a glance

  • Drugs Cetuximab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms FLEET
  • Most Recent Events

    • 02 Mar 2018 Pooled analysis of FLEET and FLEET2 studies has been presented in UMIN registry record (Unique ID issued by UMIN:UMIN000031233; Receipt No.: R000035663).
    • 19 Oct 2015 Status changed from active, no longer recruiting to completed, as reported by University Hospital Medical Information Network - Japan record.
    • 09 Jun 2012 Additional lead investigator(Mishima H) identified as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top